Neslihan Ayhan Dönmez

Mrs. Neslihan Ayhan Dönmez

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
BABatuhan Ayhan
Batuhan Ayhan
NDNeslihan Ayhan Dönmez
Neslihan Ayhan Dönmez
ZAZeliha Deniz Ayhan
Zeliha Deniz Ayhan
Central chondrosarcoma is the second most common primary malignant bone tumour, and grade progression markedly worsens prognosis. The contributions of lipid metabolic reprogramming and epigenetic co-dysregulation to grade progression remain poorly characterised. We integrated a bulk RNA-seq discovery cohort of 53 graded central chondrosarcomas (GSE299759) with a single-cell analysis of eight chondrosarcomas (GSE184118). Because the atypical cartilaginous tumour (ACT) and dedifferentiated groups each comprised only three samples, the Grade 3 versus Grade 2 contrast was pre-specified as the primary comparison. Curated panels of 44 lipid metabolism genes and 50 epigenetic regulators were assessed by differential expression and a correlation-based connectivity ranking, evaluated by permutation testing. In the primary Grade 3 versus Grade 2 comparison, SQLE, ACACA, and FASN were upregulated (FDR < 0.05), indicating a grade-associated increase in de novo lipogenesis. In the exploratory Grade 3 versus ACT comparison, additional lipid genes (HMGCR, LDLRAP1) and the epigenetic regulators EHMT2 and SIRT2 showed altered expression, although the small ACT group limits these estimates. A connectivity ranking highlighted FASN, KMT2C, TET2, SETD5, and KDM5B; permutation testing confirmed this co-expression structure was non-random (p < 0.0001). Single-cell analysis showed FASN, SETD5, and KDM5B are expressed predominantly in malignant cells, whereas KMT2C and TET2 are not, indicating cell-type heterogeneity. De novo lipogenesis upregulation is the most consistent lipid alteration in high-grade central chondrosarcoma, nominating SQLE, ACACA, and FASN as candidates for experimental investigation.

27 October 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
NDNeslihan Ayhan Dönmez
Neslihan Ayhan Dönmez
YOYesim Oztas
Yesim Oztas
TRTuba Reçber
Tuba Reçber
Emirhan NemutluEmirhan Nemutlu
Emirhan Nemutlu
CCCagri Coskun
Cagri Coskun
SUSule Unal
Sule Unal
Background/Objectives: Hereditary hemolytic anemias (HHAs) are rare genetic disorders characterized by chronic hemolysis, systemic oxidative stress, and inflammation. Altered lipid homeostasis has previously been reported in HHAs; however, untargeted plasma lipidomic studies comparing HHA subtypes remain limited. This exploratory study aimed to characterize shared and subtype-specific plasma lipid alterations across five HHA subtypes. Methods: Forty-eight participants were enrolled, including 29 patients with HHA (6 with β-thalassemia, 5 with hereditary xerocytosis, 7 with hereditary spherocytosis, 5 with sickle cell disease, and 6 with congenital dyserythropoietic anemia) and 19 healthy controls. Plasma lipids were analyzed by untargeted liquid chromatography–quadrupole time-of-flight mass spectrometry, followed by multivariate, univariate, and lipid pathway analyses. Results: A total of 375 lipid species were putatively annotated, revealing both shared and putative subtype-specific lipid alterations across the five HHA subtypes. The putatively annotated species Cer 59:7;4O and PC 46:1 remained significantly altered after false discovery rate correction, whereas species such as PC 34:4 and Cer 42:3;2O showed only nominal subtype-specific differences. Mostly nominal alterations in individual ceramide, triglyceride, and phosphatidylcholine species were observed across most hemolytic groups relative to controls. Congenital dyserythropoietic anemia exhibited the fewest nominal differences from controls. Among the 25 species with nominal Kruskal–Wallis differences, SM 37:1;2O was the only lipid species that nominally differed from controls exclusively in this subtype. Conclusions: These exploratory, hypothesis-generating findings suggest that plasma lipidomics may help characterize lipid alterations accompanying chronic hemolysis. However, the candidate lipid species and predicted pathways require validation in larger, age-matched, independent cohorts.